AstraZeneca - Q4 and Full-Year Results Interview

LONDON, January 27, 2011 - AstraZeneca said its full-year results had outperformed guidance, with
growth in emerging markets compensating for patent expiries and pricing
pressures from Western governments.

The company said a reallocation of resources had led to growth of 16 per
cent in its emerging markets, led by China where sales broke through the $1bn
mark for the first time.

In an interview with www.cantos.com, David Brennan, CEO, said the
company had seen "a strong and resilient performance" in 2010.

He expressed disappointment about recent pipeline setbacks but said the
company had resubmitted its response to the FDA regarding Brilinta, having
already achieved approval for Brilique in Europe. He also pointed to
successes such as Vimovo and Kombiglyze.

"We've recommitted to that strategy of investment in human health, to try
to really bring new, meaningful medicines to patients," he said. "And we've
made changes in our research and development organisation to improve that,
but at the same time we've made changes across our organisation to make sure
that we're prepared for the future."

The interview and transcript are available now on
www.cantos.com/company/AstraZeneca.

Cantos.com, the online financial broadcaster, features in-depth
interviews, documentaries and webcasts with senior company executives. If you
would like to contact us, please email amanda.alexander@cantos.com or phone
+44-207-936-1352.

If you would like to contact us, please email amanda.alexander at cantos.com or phone
+44-207-936-1352.